Moleculin Biotech Inc (NASDAQ: MBRX) is a clinical-stage pharmaceutical company focused on developing drug candidates for the treatment of brain cancers and other difficult-to-treat tumors. The company generates no product revenue, funding operations entirely through equity issuances including at-the-market sales, public offerings, and warrant exercises. In FY2025, financing activities provided $27.3 million in net proceeds, including $24.8 million from warrant inducement and related transactions, $1.5 million from warrant exercises, and $1.0 million from at-the-market equity sales. Net cash used in operating activities was $22.7 million for the year ended December 31, 2025, compared to $23.9 million for the year ended December 31, 2024. Key pipeline assets include WP1066, a p-STAT3 inhibitor with more than 50 peer-reviewed publications, currently in clinical research for adult glioblastoma multiforme (GBM) and pediatric brain tumors including diffuse intrinsic pontine glioma (DIPG). The company has no sales, marketing, or distribution infrastructure as of the filing date.

Revenue model

No product revenue. The company funds operations through equity capital markets activity: at-the-market stock sales, public offerings, and warrant exercises. In FY2025, these activities generated $27.3 million in net proceeds.

Products and services

WP1066: a p-STAT3 inhibitor in clinical research for adult GBM and pediatric brain tumors including DIPG. Pipeline compounds are in development stage with no approved or commercialized products as of the 10-K filed 2026-03-18.

Customers and end markets

No commercial customers. Target patient populations include adults with glioblastoma multiforme and pediatric patients with diffuse intrinsic pontine glioma. End market is oncology, specifically malignant brain and central nervous system tumors.

Value-chain role

Drug developer operating pre-commercialization. The company sponsors clinical research and holds intangible assets classified as in-process research and development (IPR&D). It has no sales, marketing, or distribution capabilities as of the filing date.

Geographic exposure

Primary operations in the United States. Clinical and regulatory activity references FDA oversight and EU data protection frameworks, but no specific geographic revenue breakdown is disclosed in the excerpts.

Source: SEC 10-K, filed 2026-03-18

Industry: Pharmaceutical Preparations Peers: Dominari Holdings Inc Tectonic Therapeutic Inc SAB Biotherapeutics Inc Renovacor, Inc. Corvus Pharmaceuticals Inc DiaMedica Therapeutics Inc Vistagen Therapeutics Inc T2 Biosystems, Inc. Spruce Biosciences, Inc